PsychoGenics has a long-standing history of successful partnerships with several companies to provide drug discovery, in which they share discovery risk in the short-term in exchange for long-term. In a typical discovery partnership, PsychoGenics provides in vivo biology while its partner provides all chemistry and in vitro capabilities.
PsychoGenics has partnerships with Eli Lilly, Roche and Sunovion (formerly Sepracor) and has delivered several pre-clinical candidates.
PsychoGenics also has relationships with several foundations such as Cure Huntington’s Disease Initiative (CHDI), Spinal Muscular Atrophy Foundation (SMAF) and The Michael J. Fox Foundation (MJFF).